Source-Free Domain Adaptation for Medical Image Segmentation via Prototype-Anchored Feature Alignment and Contrastive Learning
This addresses privacy concerns in medical imaging by enabling adaptation without access to source data, though it is incremental as it builds on existing SFDA approaches.
The paper tackles the problem of source-free domain adaptation for medical image segmentation by proposing a two-stage framework that aligns target features with source prototypes and uses contrastive learning, achieving superior performance in cross-modality tasks compared to state-of-the-art methods.
Unsupervised domain adaptation (UDA) has increasingly gained interests for its capacity to transfer the knowledge learned from a labeled source domain to an unlabeled target domain. However, typical UDA methods require concurrent access to both the source and target domain data, which largely limits its application in medical scenarios where source data is often unavailable due to privacy concern. To tackle the source data-absent problem, we present a novel two-stage source-free domain adaptation (SFDA) framework for medical image segmentation, where only a well-trained source segmentation model and unlabeled target data are available during domain adaptation. Specifically, in the prototype-anchored feature alignment stage, we first utilize the weights of the pre-trained pixel-wise classifier as source prototypes, which preserve the information of source features. Then, we introduce the bi-directional transport to align the target features with class prototypes by minimizing its expected cost. On top of that, a contrastive learning stage is further devised to utilize those pixels with unreliable predictions for a more compact target feature distribution. Extensive experiments on a cross-modality medical segmentation task demonstrate the superiority of our method in large domain discrepancy settings compared with the state-of-the-art SFDA approaches and even some UDA methods. Code is available at https://github.com/CSCYQJ/MICCAI23-ProtoContra-SFDA.